Depuydt Eva, Broeckx Sarah Y, Van Hecke Lore, Chiers Koen, Van Brantegem Leen, van Schie Hans, Beerts Charlotte, Spaas Jan H, Pille Frederik, Martens Ann
Global Stem cell Technology, Part of Boehringer Ingelheim, Evergem, Belgium.
Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Front Vet Sci. 2021 Mar 5;8:641441. doi: 10.3389/fvets.2021.641441. eCollection 2021.
Tendon injuries are very common in horses and jeopardize the athletic performance, and due to the high risk of reinjury may lead to early retirement. The use of mesenchymal stem cells for the treatment of equine tendon disease is widely investigated because of their regenerative potential. The objective of this study is to investigate the safety and efficacy of equine allogeneic tenogenic primed mesenchymal stem cells (tpMSCs) for the management of tendinitis in horses. A core lesion was surgically induced in the superficial digital flexor tendon of both forelimbs of eight horses. After 7 days, one forelimb was treated with tpMSCs, while the contralateral forelimb served as an intra-individual control and was treated with saline. A prescribed exercise program was started. All horses underwent a daily clinical evaluation throughout the entire study period of 112 days. Blood samples were taken at different time points for hematological and biochemical analysis. Tendon assessment, lameness examination, ultrasound assessment and ultrasound tissue characterization (UTC) were performed at regular time intervals. At the end of the study period, the superficial digital flexor tendons were evaluated macroscopically and histologically. No suspected or serious adverse events occurred during the entire study period. There was no difference in local effects including heat and pain to pressure between a single intralesional injection of allogeneic tpMSCs and a single intralesional injection with saline. A transient moderate local swelling was noted in the tpMSC treated limbs, which dissipated by day 11. Starting at a different time point depending on the parameter, a significant improvement was observed in the tpMSC treated limbs compared to the placebo for echogenicity score, fiber alignment score, anterior-posterior thickness of the tendon and echo type by UTC assessment. Immunohistochemistry 112 days post-injection revealed that the amount of collagen type I and Von Willebrand factor were significantly higher in the tendon tissue of the tpMSC group, while the amount of collagen type III and smooth muscle actin was significantly lower. Equine allogeneic tenogenic primed mesenchymal stem cells were shown to be well-tolerated and may be effective for the management of tendon injuries.
肌腱损伤在马匹中非常常见,会危及运动表现,且由于再次受伤的风险很高,可能导致马匹过早退役。由于间充质干细胞具有再生潜力,因此其用于治疗马肌腱疾病的研究受到广泛关注。本研究的目的是调查马同种异体肌腱源性预分化间充质干细胞(tpMSCs)治疗马肌腱炎的安全性和有效性。在8匹马的双前肢指浅屈肌腱上手术制造一个核心损伤。7天后,一个前肢用tpMSCs治疗,而对侧前肢作为个体内对照,用生理盐水治疗。开始规定的运动计划。在整个112天的研究期间,所有马匹每天都接受临床评估。在不同时间点采集血样进行血液学和生化分析。定期进行肌腱评估、跛行检查、超声评估和超声组织特征分析(UTC)。在研究期结束时,对指浅屈肌腱进行宏观和组织学评估。在整个研究期间未发生疑似或严重不良事件。同种异体tpMSCs单次病灶内注射与生理盐水单次病灶内注射相比,在包括热感和压痛在内的局部效应方面没有差异。在接受tpMSCs治疗的肢体中观察到短暂的中度局部肿胀,在第11天消散。根据参数不同,从不同时间点开始,与安慰剂相比,接受tpMSCs治疗的肢体在UTC评估的回声评分、纤维排列评分、肌腱前后厚度和回声类型方面有显著改善。注射后112天的免疫组织化学显示,tpMSC组肌腱组织中I型胶原蛋白和血管性血友病因子的含量显著更高,而III型胶原蛋白和平滑肌肌动蛋白的含量显著更低。马同种异体肌腱源性预分化间充质干细胞显示出良好的耐受性,可能对肌腱损伤的治疗有效。